These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 27503643)
1. Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria. Rens C; Laval F; Daffé M; Denis O; Frita R; Baulard A; Wattiez R; Lefèvre P; Fontaine V Antimicrob Agents Chemother; 2016 Oct; 60(10):6193-9. PubMed ID: 27503643 [TBL] [Abstract][Full Text] [Related]
2. Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria. Soetaert K; Rens C; Wang XM; De Bruyn J; Lanéelle MA; Laval F; Lemassu A; Daffé M; Bifani P; Fontaine V; Lefèvre P Antimicrob Agents Chemother; 2015 Aug; 59(8):5057-60. PubMed ID: 26033733 [TBL] [Abstract][Full Text] [Related]
3. I3-Ag85 effect on phthiodiolone dimycocerosate synthesis. Rens C; Laval F; Wattiez R; Lefèvre P; Dufrasne F; Daffé M; Fontaine V Tuberculosis (Edinb); 2018 Jan; 108():93-95. PubMed ID: 29523333 [TBL] [Abstract][Full Text] [Related]
4. Aloe Emodin Reduces Phthiodiolone Dimycocerosate Potentiating Vancomycin Susceptibility on Mycobacteria. Rens C; Ceyssens PJ; Laval F; Lefèvre P; Mathys V; Daffé M; Fontaine V Indian J Microbiol; 2018 Sep; 58(3):393-396. PubMed ID: 30013284 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Parrish NM; Houston T; Jones PB; Townsend C; Dick JD Antimicrob Agents Chemother; 2001 Apr; 45(4):1143-50. PubMed ID: 11257028 [TBL] [Abstract][Full Text] [Related]
6. F420H2 Is Required for Phthiocerol Dimycocerosate Synthesis in Mycobacteria. Purwantini E; Daniels L; Mukhopadhyay B J Bacteriol; 2016 Aug; 198(15):2020-8. PubMed ID: 27185825 [TBL] [Abstract][Full Text] [Related]
7. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin. Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557 [TBL] [Abstract][Full Text] [Related]
8. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. Taneja NK; Tyagi JS J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560 [TBL] [Abstract][Full Text] [Related]
9. [The effect of emetine hydrochloride on the growth of different mycobacteria strains]. Schwartz E Zentralbl Bakteriol Orig; 1969 Dec; 212(1):115-25. PubMed ID: 4989350 [No Abstract] [Full Text] [Related]
10. Characterization of Tetrahydrolipstatin and Stereoderivatives on the Inhibition of Essential Mycobacterium tuberculosis Lipid Esterases. Goins CM; Sudasinghe TD; Liu X; Wang Y; O'Doherty GA; Ronning DR Biochemistry; 2018 Apr; 57(16):2383-2393. PubMed ID: 29601187 [TBL] [Abstract][Full Text] [Related]
11. Cyclophostin and Cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases. Nguyen PC; Madani A; Santucci P; Martin BP; Paudel RR; Delattre S; Herrmann JL; Spilling CD; Kremer L; Canaan S; Cavalier JF Int J Antimicrob Agents; 2018 Apr; 51(4):651-654. PubMed ID: 29241819 [TBL] [Abstract][Full Text] [Related]
13. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors. Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902 [TBL] [Abstract][Full Text] [Related]
14. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development. Bailo R; Bhatt A; Aínsa JA Biochem Pharmacol; 2015 Aug; 96(3):159-67. PubMed ID: 25986884 [TBL] [Abstract][Full Text] [Related]
15. Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium. Gustine JN; Au MB; Haserick JR; Hett EC; Rubin EJ; Gibson FC; Deng LL Curr Microbiol; 2019 Apr; 76(4):398-409. PubMed ID: 30603964 [TBL] [Abstract][Full Text] [Related]
16. [Studies of the resistance of mycobacteria]. Savov N Vet Med Nauki; 1973; 10(2):39-49. PubMed ID: 4213759 [No Abstract] [Full Text] [Related]
17. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry. Akselband Y; Cabral C; Shapiro DS; McGrath P J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276 [TBL] [Abstract][Full Text] [Related]
18. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
19. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. Bhakta S; Besra GS; Upton AM; Parish T; Sholto-Douglas-Vernon C; Gibson KJ; Knutton S; Gordon S; DaSilva RP; Anderton MC; Sim E J Exp Med; 2004 May; 199(9):1191-9. PubMed ID: 15117974 [TBL] [Abstract][Full Text] [Related]
20. Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant mycobacteria. Pruksakorn P; Arai M; Kotoku N; Vilchèze C; Baughn AD; Moodley P; Jacobs WR; Kobayashi M Bioorg Med Chem Lett; 2010 Jun; 20(12):3658-63. PubMed ID: 20483615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]